| Lipidated peptides derived from intracellular loops 2 and 3 of the urotensin II receptor act as biased allosteric ligands. | Lipidated peptides derived from intracellular loops 2 and 3 of the urotensin II receptor act as biased allosteric ligands.
Nassour H, Hoang TA, Martin RD, Dallagnol JCC, Billard É, Létourneau M, Novellino E, Carotenuto A, Allen BG, Tanny JC, Fournier A, Hébert TE, Chatenet D., Free PMC Article | 12/11/2021 |
| Urotensin II receptor expression in patients with ulcerative colitis: a pilot study. | Urotensin II receptor expression in patients with ulcerative colitis: a pilot study.
Gravina AG, Dallio M, Tuccillo C, Martorano M, Abenavoli L, Luzza F, Stiuso P, Lama S, Grieco P, Merlino F, Caraglia M, Loguercio C, Federico A. | 05/15/2021 |
| Novel Mutations in UTS2R are Associated with Adolescent Idiopathic Scoliosis in the Chinese Population. | Novel Mutations in UTS2R are Associated with Adolescent Idiopathic Scoliosis in the Chinese Population.
Dai Z, Wang Y, Wu Z, Feng Z, Liu Z, Qiu Y, Cheng JC, Xu L, Zhu Z. | 05/1/2021 |
| ligand-induced activation of the chemokine receptor CXCR4 and the urotensin 2 receptor UTS2R, triggers a marked reduction in the biogenesis of autophagosomes. | Chemotactic G protein-coupled receptors control cell migration by repressing autophagosome biogenesis.
Coly PM, Perzo N, Le Joncour V, Lecointre C, Schouft MT, Desrues L, Tonon MC, Wurtz O, Gandolfo P, Castel H, Morin F., Free PMC Article | 11/18/2017 |
| The role of Urotensin-II receptor in vasoconstriction and in the development of digestive tract cancers | Urotensin-II Receptor: A Double Identity Receptor Involved in Vasoconstriction and in the Development of Digestive Tract Cancers and other Tumors.
Federico A, Zappavigna S, Dallio M, Misso G, Merlino F, Loguercio C, Novellino E, Grieco P, Caraglia M. | 10/14/2017 |
| UII/GPR14 signaling was involved in the DSS-induced colonic inflammation and its inhibition may serve as a potential therapeutic target, which may be associated with the NF-kappaB signaling pathway. | UII/GPR14 is involved in NF-κB-mediated colonic inflammation in vivo and in vitro.
Yang Y, Zhang J, Chen X, Wu T, Xu X, Cao G, Li H, Li Y. | 03/11/2017 |
| UTII-R expression on biopsy was associated with Gleason upgrading and pathology upstaging in prostate cancer patients. | Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer.
De Cobelli O, Buonerba C, Terracciano D, Bottero D, Lucarelli G, Bove P, Altieri V, Coman I, Perdonà S, Facchini G, Berretta M, Di Lorenzo G, Grieco P, Novellino E, Franco R, Caraglia M, Manini C, Mirone V, De Placido S, Sonpavde G, Ferro M., Free PMC Article | 09/10/2016 |
| Urotensin II can induce the proliferation of BEL-7402 cells via the urotensin receptor mediated PKC/ERK/p38 MAPK signaling pathways. | Up-regulation of urotensin II and its receptor contributes to human hepatocellular carcinoma growth via activation of the PKC, ERK1/2, and p38 MAPK signaling pathways.
Yu XT, Wang PY, Shi ZM, Dong K, Feng P, Wang HX, Wang XJ., Free PMC Article | 09/5/2015 |
| Report interaction of urantide with urotensin II receptor. | Urantide conformation and interaction with the urotensin-II receptor.
Brancaccio D, Limatola A, Campiglia P, Gomez-Monterrey I, Novellino E, Grieco P, Carotenuto A. | 04/11/2015 |
| UTR protein and mRNA levels were increased in colon cancer cell lines and in colon adenoma and adenocarcinoma. UTR appears to be involved in the regulation of colon cancer cell invasion and motility. | Urotensin-II receptor is over-expressed in colon cancer cell lines and in colon carcinoma in humans.
Federico A, Zappavigna S, Romano M, Grieco P, Luce A, Marra M, Gravina AG, Stiuso P, D'Armiento FP, Vitale G, Tuccillo C, Novellino E, Loguercio C, Caraglia M. | 10/25/2014 |
| High UTR expression is an independent prognostic factor of good prognosis for non muscle invasive bladder transitional cancer. | Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion.
Franco R, Zappavigna S, Gigantino V, Luce A, Cantile M, Cerrone M, Facchini G, Perdonà S, Pignata S, Di Lorenzo G, Chieffi S, Vitale G, De Sio M, Sgambato A, Botti G, Yousif AM, Novellino E, Grieco P, Caraglia M., Free PMC Article | 08/30/2014 |
| family-based analysis of association between blood pressure, glomerular filtration and genes of the urotensin-II pathway (urotensin-II, urotensin-II related peptide, urotensin-II receptor) saturated with 28 tagging single nucleotide polymorphisms | Urotensin-II system in genetic control of blood pressure and renal function.
Debiec R, Christofidou P, Denniff M, Bloomer LD, Bogdanski P, Wojnar L, Musialik K, Charchar FJ, Thompson JR, Waterworth D, Song K, Vollenweider P, Waeber G, Zukowska-Szczechowska E, Samani NJ, Lambert D, Tomaszewski M., Free PMC Article | 08/30/2014 |
| Data suggest that UTS2R in aortic endothelium is involved in development of diabetes-associated atherosclerosis; diabetes-associated plaque development is attenuated by urotensin II/UTS2R antagonism in in vitro setting. | Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes.
Watson AM, Olukman M, Koulis C, Tu Y, Samijono D, Yuen D, Lee C, Behm DJ, Cooper ME, Jandeleit-Dahm KA, Calkin AC, Allen TJ. | 11/2/2013 |
| Data show that vasoactive peptide urotensin II receptor and GABA(A)R are co-expressed in cerebellar glial cells from rat brain slices, in human native astrocytes and in glioma cell line. | Down-regulation of GABA(A) receptor via promiscuity with the vasoactive peptide urotensin II receptor. Potential involvement in astrocyte plasticity.
Desrues L, Lefebvre T, Lecointre C, Schouft MT, Leprince J, Compère V, Morin F, Proust F, Gandolfo P, Tonon MC, Castel H., Free PMC Article | 09/22/2012 |
| presence of functional nuclear UT in various rat and monkey tissues as well as in human cell lines | Presence of urotensin-II receptors at the cell nucleus: specific tissue distribution and hypoxia-induced modulation.
Nguyen TT, Létourneau M, Chatenet D, Fournier A. | 06/16/2012 |
| Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells. | Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells.
Grieco P, Franco R, Bozzuto G, Toccacieli L, Sgambato A, Marra M, Zappavigna S, Migaldi M, Rossi G, Striano S, Marra L, Gallo L, Cittadini A, Botti G, Novellino E, Molinari A, Budillon A, Caraglia M. | 07/23/2011 |
| hUII may deteriorate monocrotaline-induced cardiac hypertrophy mainly through a vasoconstriction of the pulmonary artery and partly through the suppression of ANP secretion. | Urotensin II receptor antagonist attenuates monocrotaline-induced cardiac hypertrophy in rats.
Gao S, Oh YB, Shah A, Park WH, Chung MJ, Lee YH, Kim SH. | 01/15/2011 |
| This study demonstrates that UT receptor is expressed on the endothelium of HCC. U-II/UT receptor system is involved in HCC function and it involves endothelium and NO pathway. | Urotensin II: a novel target in human corpus cavernosum.
d'Emmanuele di Villa Bianca R, Cirino G, Mitidieri E, Coletta C, Grassia G, Roviezzo F, Grieco P, Novellino E, Imbimbo C, Mirone V, Sorrentino R. | 10/4/2010 |
| An increased sensitivity to U-II in preeclampsia might be achieved by upregulation of placental U-II receptors. | Upregulation of urotensin II receptor in preeclampsia causes in vitro placental release of soluble vascular endothelial growth factor receptor 1 in hypoxia.
Gould PS, Gu M, Liao J, Ahmad S, Cudmore MJ, Ahmed A, Vatish M. | 07/19/2010 |
| These findings suggest that the intrahepatic UII/UT system has an important pathophysiological role in cirrhosis and portal hypertension. | Increased expression of urotensin II and GPR14 in patients with cirrhosis and portal hypertension.
Liu D, Chen J, Wang J, Zhang Z, Ma X, Jia J, Wang Y. | 07/19/2010 |
| Demonstrate an important role for UTS2R in the pathogenesis of atherosclerosis. The use of UTS2R receptor antagonists may provide a beneficial tool in the management of this debilitating disease process. | Targeted overexpression of the human urotensin receptor transgene in smooth muscle cells: effect of UT antagonism in ApoE knockout mice fed with Western diet.
Papadopoulos P, Bousette N, Al-Ramli W, You Z, Behm DJ, Ohlstein EH, Harrison SM, Douglas SA, Giaid A. | 01/21/2010 |
| Urotensin II receptor activation in vivo enhanced the adrenocortical expression of immunoreactive aldosterone synthase. | Expression and functional role of urotensin-II and its receptor in the adrenal cortex and medulla: novel insights for the pathophysiology of primary aldosteronism.
Giuliani L, Lenzini L, Antonello M, Aldighieri E, Belloni AS, Fassina A, Gomez-Sanchez C, Rossi GP. | 01/21/2010 |
| To understand the molecular interactions of hU-II and certain antagonists with the hUT-II receptor, a model of the hUT-II receptor in an active conformation with all its connecting loops was constructed by homology modeling. | Three-dimensional model of the human urotensin-II receptor: docking of human urotensin-II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model.
Lescot E, Sopkova-de Oliveira Santos J, Colloc'h N, Rodrigo J, Milazzo-Segalas I, Bureau R, Rault S. | 01/21/2010 |
| REsults describe the differential expression of urotensin II receptors in cardiovascular tissues from rats and humans and suggest that it may account for the diverse vascular actions reported for urotensin-II. | Immunocytochemical localization of the urotensin-II receptor, UT, to rat and human tissues: relevance to function.
Maguire JJ, Kuc RE, Kleinz MJ, Davenport AP. | 01/21/2010 |
| Results describe the solution structure of urotensin-II receptor extracellular loop III and characterize its interaction with urotensin-II. | Solution structure of urotensin-II receptor extracellular loop III and characterization of its interaction with urotensin-II.
Boivin S, Ségalas-Milazzo I, Guilhaudis L, Oulyadi H, Fournier A, Davoust D. | 01/21/2010 |